540 related articles for article (PubMed ID: 28044137)
1. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
[No Abstract] [Full Text] [Related]
2. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study.
Chen F; Shen C; Pang X; Zhang Z; Deng Y; Han L; Chen X; Zhang J; Xia Q; Qian Y
Transpl Infect Dis; 2020 Feb; 22(1):e13199. PubMed ID: 31627248
[TBL] [Abstract][Full Text] [Related]
3. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
De Pascale G; Montini L; Pennisi M; Bernini V; Maviglia R; Bello G; Spanu T; Tumbarello M; Antonelli M
Crit Care; 2014 May; 18(3):R90. PubMed ID: 24887101
[TBL] [Abstract][Full Text] [Related]
4. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study.
Chen CY; Yang KY; Peng CK; Sheu CC; Chan MC; Feng JY; Wang SH; Chen CM; Zheng ZR; Liang SJ; Lin YC;
Sci Rep; 2022 May; 12(1):7501. PubMed ID: 35525867
[TBL] [Abstract][Full Text] [Related]
6. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
Geng TT; Xu X; Huang M
Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
8. Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria.
Choe J; Sohn YM; Jeong SH; Park HJ; Na SJ; Huh K; Suh GY; Jeon K
Ther Adv Respir Dis; 2019; 13():1753466619885529. PubMed ID: 31680646
[TBL] [Abstract][Full Text] [Related]
9. A prediction tool for nosocomial multi-drug Resistant Gram-Negative Bacilli infections in critically ill patients - prospective observational study.
Vasudevan A; Mukhopadhyay A; Li J; Yuen EG; Tambyah PA
BMC Infect Dis; 2014 Nov; 14():615. PubMed ID: 25420613
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.
Chen Z; Shi X
Medicine (Baltimore); 2018 Sep; 97(38):e12467. PubMed ID: 30235740
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
[TBL] [Abstract][Full Text] [Related]
14. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
Maseda E; Denis SE; Riquelme A; Gilsanz F
Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
[No Abstract] [Full Text] [Related]
16. Clinico-microbiological profile and outcomes of nosocomial sepsis in an Indian tertiary care hospital--a prospective cohort study.
Saravu K; Prasad M; Eshwara VK; Mukhopadhyay C
Pathog Glob Health; 2015 Jul; 109(5):228-35. PubMed ID: 26184918
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
[TBL] [Abstract][Full Text] [Related]
18. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
Werarak P; Kiratisin P; Thamlikitkul V
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic/adjuvant combinations (ceftriaxone + sulbactam + adjuvant disodium edetate) as an alternative empiric therapy for the treatment of nosocomial infections: Results of a retrospective study.
Chakravorty S; Arun P
Indian J Cancer; 2017; 54(4):685-690. PubMed ID: 30082559
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection.
Qu J; Feng C; Li H; Lv X
Int J Antimicrob Agents; 2021 Mar; 57(3):106284. PubMed ID: 33484833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
